New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell ...
Paradigm Gold Corporation (TSXV: PDQ) ("Paradigm" or the "Company") has extended the closing of its previously announced ...
Nagpur: The department of basic science and humanities, KDK College of Engineering, organised the 42nd Fresher's Day on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback